{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:35:15Z","timestamp":1793158515804,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13760-026-03110-z","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:22:15Z","timestamp":1781677335000},"page":"1603-1612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of secondary progressive multiple sclerosis in a real word retrospective cohort: the role of clinical factors and disease-modifying therapy patterns"],"prefix":"10.1007","volume":"126","author":[{"given":"Pegah","family":"Mohaghegh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fardin","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsoon","family":"Talaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"2","key":"3110_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple Sclerosis. N Engl J Med 378(2):169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"issue":"4","key":"3110_CR2","doi-asserted-by":"publisher","first-page":"e0214738","DOI":"10.1371\/journal.pone.0214738","volume":"14","author":"M Azami","year":"2019","unstructured":"Azami M, YektaKooshali MH, Shohani M, Khorshidi A et al (2019) Epidemiology of multiple sclerosis in Iran: A systematic review and meta-analysis. PLoS ONE 14(4):e0214738. https:\/\/doi.org\/10.1371\/journal.pone.0214738","journal-title":"PLoS ONE"},{"key":"3110_CR3","doi-asserted-by":"publisher","first-page":"175628642211468","DOI":"10.1177\/17562864221146836","volume":"16","author":"A Bayas","year":"2023","unstructured":"Bayas A, Christ M, Faissner S, Klehmet J, Pul R, Skripuletz T et al (2023) Disease-modifying therapies for relapsing\/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials. Ther Adv Neurol Disord 16:17562864221146836. https:\/\/doi.org\/10.1177\/17562864221146836","journal-title":"Ther Adv Neurol Disord"},{"issue":"13","key":"3110_CR4","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1177\/1352458512445941","volume":"22","author":"R Bergamaschi","year":"2016","unstructured":"Bergamaschi R, Quaglini S, Tavazzi E, Amato MP, Paolicelli D, Zipoli V, Romani A et al (2016) Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler 22(13):1732\u20131740. https:\/\/doi.org\/10.1177\/1352458512445941","journal-title":"Mult Scler"},{"issue":"3","key":"3110_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/13524585231225929","volume":"30","author":"FS Teni","year":"2024","unstructured":"Teni FS, Machado A, Fink K, Gyllensten H, Hillert J, Friberg E (2024) Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden. Mult Scler 30(3):419\u2013431. https:\/\/doi.org\/10.1177\/13524585231225929","journal-title":"Mult Scler"},{"issue":"7","key":"3110_CR6","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s12325-020-01367-1","volume":"37","author":"J Bowen","year":"2020","unstructured":"Bowen J, Mehta R, Pelletier C, Tian M, Noxon V, Johnson BH et al (2020) Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. Adv therapy 37(7):3163\u20133177. https:\/\/doi.org\/10.1007\/s12325-020-01367-1","journal-title":"Adv therapy"},{"key":"3110_CR7","doi-asserted-by":"publisher","first-page":"175628642412397","DOI":"10.1177\/17562864241239740","volume":"17","author":"N Frahm","year":"2024","unstructured":"Frahm N, Ellenberger D, Stahmann A, Fneish F, L\u00fcftenegger D, Salmen HC et al (2024) Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry. Ther Adv Neurol Disord 17:17562864241239740. https:\/\/doi.org\/10.1177\/17562864241239740","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"3110_CR8","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC (2020) Treatment of Multiple Sclerosis: A Review. Am J Med 133(12):1380\u20131390e2. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049","journal-title":"Am J Med"},{"key":"3110_CR9","doi-asserted-by":"publisher","first-page":"175628642412391","DOI":"10.1177\/17562864241239117","volume":"17","author":"J Guo","year":"2024","unstructured":"Guo J, Wu J, Wang L, Liu H, Wu X, Yang H et al (2024) Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China. Ther Adv Neurol Disord 17:17562864241239117. https:\/\/doi.org\/10.1177\/17562864241239117","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"3110_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1352458508096687","volume":"15","author":"A Gajofatto","year":"2009","unstructured":"Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E (2009) Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 15(1):50\u201358. https:\/\/doi.org\/10.1177\/1352458508096687","journal-title":"Mult Scler"},{"issue":"6","key":"3110_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1177\/1352458512463764","volume":"19","author":"H Tedeholm","year":"2013","unstructured":"Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C et al (2013) Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler 19(6):765\u2013774. https:\/\/doi.org\/10.1177\/1352458512463764","journal-title":"Mult Scler"},{"issue":"2","key":"3110_CR12","doi-asserted-by":"publisher","first-page":"205521731878334","DOI":"10.1177\/2055217318783347","volume":"4","author":"F Coret","year":"2018","unstructured":"Coret F, P\u00e9rez-Miralles FC, Gasc\u00f3n F, Alcal\u00e1 C, Navarr\u00e9 A, Bernad A et al (2018) Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Multiple Scler J - experimental translational Clin 4(2):2055217318783347. https:\/\/doi.org\/10.1177\/2055217318783347","journal-title":"Multiple Scler J - experimental translational Clin"},{"issue":"8","key":"3110_CR13","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1007\/s00415-020-09850-z","volume":"267","author":"E Misicka","year":"2020","unstructured":"Misicka E, Sept C, Briggs FBS (2020) Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors. J Neurol 267(8):2328\u20132339. https:\/\/doi.org\/10.1007\/s00415-020-09850-z","journal-title":"J Neurol"},{"key":"3110_CR14","doi-asserted-by":"publisher","first-page":"103691","DOI":"10.1016\/j.msard.2022.103691","volume":"60","author":"F Faraji","year":"2022","unstructured":"Faraji F, Ahmadi F, Mohaghegh P, Talaie A (2022) Temporal Incidence and Prevalence Trends of Multiple Sclerosis in Markazi Province, Iran. Multiple Scler Relat disorders 60:103691. https:\/\/doi.org\/10.1016\/j.msard.2022.103691","journal-title":"Multiple Scler Relat disorders"},{"key":"3110_CR15","doi-asserted-by":"publisher","first-page":"104231","DOI":"10.1016\/j.msard.2022.104231","volume":"68","author":"F Faraji","year":"2022","unstructured":"Faraji F, Mohaghegh P, Talaie A (2022) Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran. Multiple Scler Relat disorders 68:104231. https:\/\/doi.org\/10.1016\/j.msard.2022.104231","journal-title":"Multiple Scler Relat disorders"},{"issue":"2","key":"3110_CR16","doi-asserted-by":"publisher","first-page":"e00552","DOI":"10.1016\/j.neurot.2025.e00552","volume":"22","author":"S Toscano","year":"2025","unstructured":"Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Fermo L, S., et al (2025) First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics: J Am Soc Experimental Neurother 22(2):e00552. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00552","journal-title":"Neurotherapeutics: J Am Soc Experimental Neurother"},{"issue":"2","key":"3110_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A et al (2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA 321(2):175\u2013187. https:\/\/doi.org\/10.1001\/jama.2018.20588","journal-title":"JAMA"},{"issue":"4","key":"3110_CR18","doi-asserted-by":"publisher","first-page":"e26658","DOI":"10.1016\/j.heliyon.2024.e26658","volume":"10","author":"M Ghiasian","year":"2024","unstructured":"Ghiasian M, Bawand R, Jabarzadeh S, Moradi A (2024) Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis. Heliyon 10(4):e26658. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26658","journal-title":"Heliyon"},{"key":"3110_CR19","doi-asserted-by":"publisher","unstructured":"Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree BA, Havrdova EK et al (2022) Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. Neurology(R) neuroimmunology & neuroinflammation, 10(1):e200064. https:\/\/doi.org\/10.1212\/NXI.0000000000200064","DOI":"10.1212\/NXI.0000000000200064"},{"issue":"6","key":"3110_CR20","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1007\/s00415-024-12303-6","volume":"271","author":"A Glaser","year":"2024","unstructured":"Glaser A, Butzkueven H, van der Walt A, Gray O, Spelman T, Zhu C et al (2024) Big Multiple Sclerosis Data network: an international registry research network. J Neurol 271(6):3616\u20133624. https:\/\/doi.org\/10.1007\/s00415-024-12303-6","journal-title":"J Neurol"},{"issue":"6","key":"3110_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/jnnp-2024-334700","volume":"96","author":"J Lorscheider","year":"2025","unstructured":"Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M et al (2025) Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network. J Neurol Neurosurg Psychiatry 96(6):606\u2013615. https:\/\/doi.org\/10.1136\/jnnp-2024-334700","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3110_CR22","doi-asserted-by":"publisher","first-page":"175628642513572","DOI":"10.1177\/17562864251357276","volume":"18","author":"S Laaksonen","year":"2025","unstructured":"Laaksonen S, Sucksdorff M, Vuorimaa A, Kuhle J, Nylund M, Rajander J et al (2025) Predictors of risk of secondary progression in multiple sclerosis. Ther Adv Neurol Disord 18:17562864251357276. https:\/\/doi.org\/10.1177\/17562864251357276","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"3110_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1352458519868990","volume":"26","author":"A Fambiatos","year":"2020","unstructured":"Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A et al (2020) Risk of secondary progressive multiple sclerosis: A longitudinal study. Mult Scler 26(1):79\u201390. https:\/\/doi.org\/10.1177\/1352458519868990","journal-title":"Mult Scler"},{"issue":"11","key":"3110_CR24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1136\/jnnp-2025-335958","volume":"96","author":"A Zangh\u00ec","year":"2025","unstructured":"Zangh\u00ec A, Copetti M, Avolio C, Paolicelli D, Romeo MAL, Patti F et al (2025) Multiple sclerosis from onset to secondary progression: a 30-year Italian register study. J Neurol Neurosurg Psychiatry 96(11):1061\u20131069. https:\/\/doi.org\/10.1136\/jnnp-2025-335958","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"3110_CR25","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1007\/s00415-019-09489-5","volume":"268","author":"H Inojosa","year":"2021","unstructured":"Inojosa H, Proschmann U, Akg\u00fcn K, Ziemssen T (2021) A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. J Neurol 268(4):1210\u20131221. https:\/\/doi.org\/10.1007\/s00415-019-09489-5","journal-title":"J Neurol"},{"issue":"6","key":"3110_CR26","doi-asserted-by":"publisher","first-page":"fcae422","DOI":"10.1093\/braincomms\/fcae422","volume":"6","author":"L Pontieri","year":"2024","unstructured":"Pontieri L, Greene N, Wandall-Holm MF, Geertsen SS, Asgari N, Jensen HB et al (2024) Patterns and predictors of multiple sclerosis phenotype transition. Brain Commun 6(6):fcae422. https:\/\/doi.org\/10.1093\/braincomms\/fcae422","journal-title":"Brain Commun"},{"issue":"5","key":"3110_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00415-026-13802-4","volume":"273","author":"TAN Fuchs","year":"2026","unstructured":"Fuchs TAN, Schoonheim MM, Strijbis EMM, Jelgerhuis JR, Horakova D, Havrdova EK et al (2026) Predicting disease progression in multiple sclerosis with clinically accessible information and technology. J Neurol 273(5):281. https:\/\/doi.org\/10.1007\/s00415-026-13802-4","journal-title":"J Neurol"},{"issue":"2","key":"3110_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/jcm12020685","volume":"12","author":"E Virgilio","year":"2023","unstructured":"Virgilio E, Vecchio D, Sarnelli MF, Solara V, Cantello R, Comi C (2023) Early Predictors of Disability and Cognition in Multiple Sclerosis Patients: A Long-Term Retrospective Analysis. J Clin Med 12(2):685. https:\/\/doi.org\/10.3390\/jcm12020685","journal-title":"J Clin Med"},{"issue":"2","key":"3110_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00415-026-13704-5","volume":"273","author":"J Guo","year":"2026","unstructured":"Guo J, Olsson T, Alfredsson L, Hedstr\u00f6m AK (2026) Disability progression in multiple sclerosis: a latent class analysis of predictors. J Neurol 273(2):157. https:\/\/doi.org\/10.1007\/s00415-026-13704-5","journal-title":"J Neurol"},{"issue":"1","key":"3110_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/14737175.2021.1847085","volume":"21","author":"HS Ng","year":"2021","unstructured":"Ng HS, Zhu F, Kingwell E, Zhao Y, Yao S, Ekuma O et al (2021) Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Rev Neurother 21(1):131\u2013140. https:\/\/doi.org\/10.1080\/14737175.2021.1847085","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"3110_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1177\/13524585211063403","volume":"28","author":"HS Ng","year":"2022","unstructured":"Ng HS, Zhu F, Kingwell E, Zhao Y, Yao S, Ekuma O et al (2022) Disease-modifying drugs for multiple sclerosis and subsequent health service use. Mult Scler 28(4):583\u2013596. https:\/\/doi.org\/10.1177\/13524585211063403","journal-title":"Mult Scler"},{"key":"3110_CR32","doi-asserted-by":"publisher","first-page":"122913","DOI":"10.1016\/j.jns.2024.122913","volume":"458","author":"EF Balcom","year":"2024","unstructured":"Balcom EF, Smyth P, Kate M, Vu K, Martins KJB, Aponte-Hao S et al (2024) Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: A retrospective cohort study from Alberta, Canada. J Neurol Sci 458:122913. https:\/\/doi.org\/10.1016\/j.jns.2024.122913","journal-title":"J Neurol Sci"},{"issue":"5","key":"3110_CR33","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14737175.2022.2061950","volume":"22","author":"S Leblanc","year":"2022","unstructured":"Leblanc S, Lefort M, Le Page E, Michel L, Leray E (2022) Trends in disease-modifying therapy use in patients with multiple sclerosis using a 10-year population-based cohort study in France. Expert Rev Neurother 22(5):411\u2013418. https:\/\/doi.org\/10.1080\/14737175.2022.2061950","journal-title":"Expert Rev Neurother"},{"key":"3110_CR34","doi-asserted-by":"publisher","first-page":"104220","DOI":"10.1016\/j.msard.2022.104220","volume":"68","author":"H Tedeholm","year":"2022","unstructured":"Tedeholm H, Piehl F, Lycke J, Link J, Stawiarz L, Burman J et al (2022) Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis. Multiple Scler Relat disorders 68:104220. https:\/\/doi.org\/10.1016\/j.msard.2022.104220","journal-title":"Multiple Scler Relat disorders"},{"key":"3110_CR35","doi-asserted-by":"publisher","first-page":"175628642312213","DOI":"10.1177\/17562864231221331","volume":"17","author":"H Butzkueven","year":"2024","unstructured":"Butzkueven H, Kalincik T, Patti F, Slee M, Weinstock-Guttman B, Buzzard K et al (2024) Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies. Ther Adv Neurol Disord 17:17562864231221331. https:\/\/doi.org\/10.1177\/17562864231221331","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"3110_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Ryerson Z, Kister L, Malpas I, C. B., et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19(4):307\u2013316. https:\/\/doi.org\/10.1016\/S1474-4422(20)30067-3","journal-title":"Lancet Neurol"},{"issue":"8","key":"3110_CR37","doi-asserted-by":"publisher","first-page":"e042480","DOI":"10.1136\/bmjopen-2020-042480","volume":"11","author":"S Braune","year":"2021","unstructured":"Braune S, Rossnagel F, Dikow H, Bergmann A, NeuroTransData Study Group (2021) Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry. BMJ open 11(8):e042480. https:\/\/doi.org\/10.1136\/bmjopen-2020-042480","journal-title":"BMJ open"},{"issue":"5","key":"3110_CR38","doi-asserted-by":"publisher","first-page":"e16583","DOI":"10.1111\/ene.16583","volume":"32","author":"M Cohen","year":"2025","unstructured":"Cohen M, Rollot F, Debouverie M, Zephir H, Vukusic S, De Seze J et al (2025) Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study. Eur J Neurol 32(5):e16583. https:\/\/doi.org\/10.1111\/ene.16583","journal-title":"Eur J Neurol"},{"issue":"2","key":"3110_CR39","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1212\/cont.0000000000001679","volume":"32","author":"EM Mowry","year":"2026","unstructured":"Mowry EM, Okuda DT, Ontaneda D (2026) Treatment of Multiple Sclerosis. Continuum (Minneapolis Minn) 32(2):541\u2013564. https:\/\/doi.org\/10.1212\/cont.0000000000001679","journal-title":"Continuum (Minneapolis Minn)"},{"key":"3110_CR40","doi-asserted-by":"publisher","first-page":"1635618","DOI":"10.3389\/fneur.2025.1635618","volume":"16","author":"G Makarevi\u010dius","year":"2025","unstructured":"Makarevi\u010dius G, Kizlaitien\u0117 R, Kaubrys G, Giedraitien\u0117 N (2025) Predictors of therapy switching to high-efficacy disease-modifying therapies in patients with multiple sclerosis: a single center, retrospective, observational study. Front Neurol 16:1635618. https:\/\/doi.org\/10.3389\/fneur.2025.1635618","journal-title":"Front Neurol"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03110-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03110-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03110-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:00:15Z","timestamp":1793156415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03110-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3110"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03110-z","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol received approval from the Vice Chancellor for Research and the Institutional Ethics Committee of Arak University of Medical Sciences (Ethics Approval No. IR.ARAKMU.REC.1402.171) in accordance with the Declaration of Helsinki guidelines. Informed consent has been obtained from all patients.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}